Smith & Nephew Valuation Multiples

Smith & Nephew Overview

About Smith & Nephew

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Founded

1937

HQ

Employees

17.3K

Website

smith-nephew.com

Sectors

Medical DevicesMedical SuppliesDeepTechHealthTech

Financials (LTM)

Revenue: $6B

EBITDA: $2B

EV

$17B

Valuation Multiples

Multiples.vc

Start free trial

Smith & Nephew Financials

Smith & Nephew reported last 12-month revenue of $6B and EBITDA of $2B.

In the same LTM period, Smith & Nephew generated $4B in gross profit, $2B in EBITDA, and $905M in net income.

Smith & Nephew P&L

In the most recent fiscal year, Smith & Nephew reported revenue of $6B and EBITDA of $2B.

Smith & Nephew expects next 12-month revenue of XXX and NTM EBITDA of XXX

Smith & Nephew Stock Performance

Smith & Nephew has current market cap of $15B, and enterprise value of $17B.

Smith & Nephew's stock price is $17.10.

Smith & Nephew Valuation Multiples

Smith & Nephew trades at 2.8x EV/Revenue multiple, and 10.6x EV/EBITDA.

Smith & Nephew Financial Valuation Multiples

As of April 21, 2026, Smith & Nephew has market cap of $15B and EV of $17B.

Equity research analysts estimate Smith & Nephew's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Smith & Nephew has a P/E ratio of 16.1x.

Smith & Nephew Margins & Growth Rates

Smith & Nephew's revenue in the last 12 month grew by 6%.

Smith & Nephew's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Smith & Nephew's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Smith & Nephew's rule of X is 44% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Smith & Nephew Public Comps

See public comps and valuation multiples for other Medical Devices and Medical Supplies comps.

Smith & Nephew M&A Activity

Smith & Nephew acquired XXX companies to date.

Last acquisition by Smith & Nephew was on XXXXXXXX, XXXXX. Smith & Nephew acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Smith & Nephew Investment Activity

Smith & Nephew invested in XXX companies to date.

Smith & Nephew made its latest investment on XXXXXXXX, XXXXX. Smith & Nephew invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).